Compounded mAbs - Cancer Therapies

Berkshire Healthcare NHS Foundation TrustcontractFind a TenderRef ocds-h6vhtk-0693deProcurement Act 2023SME suitableVCSE suitableactive
View buyer

Estimated value

£216.0m

services

Awarded value

Suppliers

0

Lots

2

0 awarded

Published

07 May 2026

Deadline 08 Jun 2026

Description

Phamacy Procurement Contract - A ranked framework for the supply and delivery of Compounded Monoclonal Antibodies (mAbs) for Intravenous Infusion for Chemotherapy indications split into 2 lots: Lot 1: High Volume Products - 5 molecules / all brands Lot 2: Lower Volume Products - 13 molecules / all brands The ranked framework will be open to the participating Trusts of the South East Pharmacy Procurement Service (SEPPS): Thames Valley and Wessex (TV&W) 1. Buckinghamshire Healthcare NHS Trust 2. Frimley Health NHS Foundation Trust 3. Hampshire Hospitals NHS Foundation Trust 4. Isle of Wight NHS Trust 5. Hampshire and Isle of Wight Healthcare NHS Foundation Trust 6. Milton Keynes University Hospital NHS Foundation Trust 7. Oxford Health NHS Foundation Trust 8. Oxford University Hospitals NHS Foundation Trust 9. Portsmouth Hospitals NHS Trust 10. Royal Berkshire NHS Foundation Trust 11. University Hospital Southampton NHS Foundation Trust South-East Coast (SEC) 12. Ashford and St. Peters’ Hospitals NHS Foundation Trust 13. Dartford and Gravesham NHS Trust 14. East Kent Hospitals University NHS Foundation Trust 15. East Sussex Healthcare NHS Trust 16. Kent Community Health NHS Trust 17. Maidstone & Tunbridge Wells NHS Trust 18. Medway NHS Foundation Trust 19. Queen Victoria Hospitals NHS Foundation Trust 20. Royal Surrey County Hospital NHS Foundation Trust 21. Surrey and Borders Partnership NHS Foundation Trust 22. Surrey and Sussex Healthcare NHS Trust 23. Sussex Community NHS Trust 24. Sussex Partnership NHS Foundation Trust 25. University Hospitals Sussex NHS Foundation Trust 26. Berkshire Healthcare NHS Foundation Trust This framework will be available for use by Trusts in East of England and London regions, but the volumes for these regions have not been included for adjudication as part of the tender process. SEC Trusts can utilise this tender for products or services not covered by the National unlicensed aseptically prepared cytotoxic medicines and mAbs framework via MPSC. Please note: we did not publish a preliminary market engagement notice (UK2) for the following reasons: - we are not seeking to further develop our requirements or procurement approach. - we have procured similar supply arrangements via the Open procedure and deployed similar conditions of participation and award criteria. These have yielded good results previously. - we have already prepared our tender pack (see attached), that detail standard NHS contractual terms which have been found to be acceptable to the supply chain. - we understand the likely suppliers who will be interested but the open notice approach gives opportunity to others looking to enter the mAbs supply market

Scope

Reference
PR BHFT 0715
Total value
£216,000,000 excluding VAT
£259,200,000 including VAT
Above the relevant threshold
Commercial tool
Standalone contract
Contract dates
01 Dec 2026 to 30 Nov 2028
Possible extension to 30 Nov 2030

Option for 2 x 12 month extension (maximum duration 4 years).

Main category
services
CPV classifications
33600000
85149000
Contract locations
UK, United Kingdom
South East England, United Kingdom
Particular suitability
Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)

Award criteria

Criteria the buyer will use to evaluate bids.

NameDescriptionTypeWeighting
Procurement Specific QuestionnairePass/Fail - see Tender Pack - ITT Instructions for detailquality0.01%
Framework Agreement T&Cs AcceptancePass/Fail - see Tender Pack - ITT Instructions for detailquality0.01%
Technical Compliance/ Technical Capability/ Quality Assurance (40%)Technical Compliance / Technical Capability/ Quality Assurance. Responses to Technical Questions - see Tender Pack - ITT Instructions for detail. Note: MHRA Licensing is Pass/Failquality39.98%
Social Value (10%)Responses to Social Value Questions - see Tender Pack - ITT Instructions for detail.quality10.00%
Shelf Life (15%)Shelf Life Assessment - see Tender Pack - ITT Instructions for detailquality15.00%
Price (35%)Assessment of Pricing Model - see Tender Pack - ITT Instructions for detailprice35.00%

Participation

Conditions suppliers must meet to bid.

See Tender Pack

Submission & procedure

Enquiry deadline
02 Jun 2026, 11:00 am
Submission deadline
08 Jun 2026, 11:15 am
Submission address
https://health-family.force.com/s/Welcome
Electronic submission
Yes
Procedure
Open procedure

Lots · 2 total

Divisions of the contract. Each lot can be awarded separately.

View all →
LotTitleEst. valueStatus
1Lot 1£170.6mactive
2Lot 2£45.4mactive